Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health

Abstract

Switch to dolutegravir with rilpivirine was associated with significant improvement in BMD and bone turnover markers compared with tenofovir-based three-drug regimens, providing a robust option for preserving bone health while continuing suppressive ART.